Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Neutropenia 1Neoplasms 1Breast Neoplasms 1

Interventions

pegfilgrastim 30Filgrastim 29Cyclophosphamide 10Docetaxel 8pegylated granulocyte colony-stimulating factor 7Etoposide 7Cytarabine 7Ciprofloxacin 5Cefepime 5eflapegrastim 4Vancomycin 4Leucovorin 4Granulocyte Colony-Stimulating Factor 4Fluorouracil 4Doxorubicin 4Peripheral Blood Stem Cell Transplantation 3Mitoxantrone 3Methotrexate 3Levofloxacin 3Irinotecan 3Idarubicin 3Daunorubicin 3Cyclosporine 3Caspofungin 3Carboplatin 3trifluridine tipiracil drug combination 2plerixafor 2liposomal amphotericin B 2Vincristine 2Topotecan 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Neutropenia × Maxy G34 × Clear all
NCT00501332 2007-12-24

Evaluation of Maxy-G34 in Breast Cancer Patients Treated With TAC (Docetaxel, Adriamycin, Cyclophosphamide) Chemotherapy

Maxygen Holdings Ltd.

Phase 2 Unknown
30 enrolled
Breast

Breast Neoplasms, Neoplasms, Neutropenia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡